Continuing cyclin-dependent kinase 4/6 inhibition in metastatic breast cancer patients previously treated with another cyclin-dependant kinase 4/6 inhibitor: a protocol for systematic review and meta-analysis
Alicia de Luna Aguilar(Hospital Clínico San Carlos), José Á. García-Sáenz(Hospital Clínico San Carlos), Manushak Avagyan(Centre international de recherche sur le cancer), Richa Shah(Centre international de recherche sur le cancer), Javier David Benítez Fuentes(Universidad de Zaragoza), Carmen Toledano Rojas(Hospital Clínico San Carlos), Alfonso Lopez de Sa Lorenzo(Hospital Clínico San Carlos), Jorge Bartolomé(Hospital Clínico San Carlos), Fernando Moreno Antón(Hospital Clínico San Carlos), Clara Frick(German Cancer Research Center)
Cited by 3
Related Papers
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
|Annals of Oncology|2011|222
Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study
|The Lancet Global Health|2023|186